The FDA based its approval of pembrolizumab on findings from the phase 2 KEYNOTE-158 trial.
|Videos|May 29, 2021
Medical World News® Wellbeing Checkup: CancerNetwork® and Sonia Jhas on Easy Exercises for Busy Professionals
Author(s)Sonia Jhas
CancerNetwork® sat down with Health and Wellness expert Sonia Jhas to discuss best practices for staying active on a busy, demanding schedule.
Advertisement
On this episode of Wellbeing Checkup from the
This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.
Advertisement
Related to this article
Industry payments to oncologists were associated with greater use of the promoted treatment, whether or not it was guideline-preferred for the patient’s cancer.
In an exploratory KEYNOTE-B15 analysis, ctDNA clearance was higher with enfortumab vedotin plus pembrolizumab than with cisplatin and gemcitabine.
Subgroup analyses of the phase 3 RASolute 302 trial showed overall survival favored daraxonrasib over chemotherapy in metastatic pancreatic cancer.
Adding pembrolizumab to carboplatin and etoposide improved response rates and OS vs chemotherapy alone in metastatic NEPC in KEYNOTE-365 cohort I.
Posters covered a companion diagnostic for niraparib plus AAP, response biomarkers for radioligand therapy, and genomic profile differences in metastatic CRPC.
Six-year NATALEE data show ribociclib plus an NSAI reduced the risk of death by 19% vs NSAI alone in HR+/HER2- early breast cancer.
Final NSABP B-42 data show 5 additional years of letrozole improved DFS, BCFI, and distant recurrence vs placebo at 15 years, with no OS difference.
Advertisement
Advertisement
Trending on CancerNetwork
1
Intismeran Plus Pembrolizumab Reduces Recurrence Risk in Resected Melanoma
2
What Pope Leo XIV’s Lung Cancer Diagnosis Could Mean for Stigma & Nihilism
3
FDA Approves Pembrolizumab in Metastatic TMB-H Solid Tumors
4
Zipalertinib May Introduce Another Option to EGFR Exon 20+ NSCLC
5